» Articles » PMID: 35013936

COX-2/PGE2 Pathway Inhibits the Ferroptosis Induced by Cerebral Ischemia Reperfusion

Overview
Journal Mol Neurobiol
Date 2022 Jan 11
PMID 35013936
Authors
Affiliations
Soon will be listed here.
Abstract

Cerebral ischemia reperfusion (I/R) injury easily develops in ischemic stroke, resulting in more serious injury. Ferroptosis is involved in cerebral I/R injury, but the mechanism remains unclear. Prostaglandin E2 (PGE2) is potential to regulate ferroptosis. This study mainly explored the regulation effects of PGE2 on ferroptosis induced by cerebral I/R. We first detected PGE2 levels and ferroptosis status in 11 human brain tissues. Then, we induced a cerebral I/R animal model to examine ferroptosis status in cerebral I/R. We further injected a ferroptosis inhibitor to define the response of the PGE2 pathway to ferroptosis. Finally, we injected PGE2 and pranoprofen to explore the regulation of the cyclooxygenases 2 (COX-2)/PGE2 pathway on ferroptosis in cerebral I/R. We found that PGE2 release was correlated with the levels of reactive oxygen species, malondialdehyde, glutathione peroxidase 4, COX-2, and Spermidine/spermine N1-acetyltransferase 1. Ferroptosis can be induced by cerebral I/R, while inhibition of ferroptosis induced by cerebral I/R can inactivate PGE2 synthases, degrade enzyme, and parts of PGE2 receptors, and reduce cerebral infarct volume. In turn, PGE2 inhibited ferroptosis through the reduction of Fe, glutathione oxidation, and lipid peroxidation, while pranoprofen, one of the COX inhibitors, played an opposite role. In conclusion, PGE2 was positively correlated with ferroptosis, inhibition of ferroptosis induced by cerebral I/R can inactivate COX-2/PGE2 pathway, and PGE2 inhibited ferroptosis induced by cerebral I/R, possibly via PGE2 receptor 3 and PGE2 receptor 4. Graphical abstract Inhibition of ferroptosis inactivates the COX-2/PGE2 pathway. Cerebral ischemia reperfusion injury induces the secretion of PGE2. After the inhibition of ferroptosis by Fer-1, the expression of cyclooxygenases (COX-1 and COX-2) decreased, and PGE2 synthases cPGES, mPGES-1, and mPGES-2 were also reduced. At the same time, the PGE2 degradation enzyme 15-PGDH was also reduced. Changes in these enzymes ultimately result in the declination of PGE2. Besides, the expression of PGE2 receptors EP3 and EP4 is also inhibited, indicating that the function they mediate is also impaired. In conclusion, after cerebral ischemia reperfusion injury, the inhibition of ferroptosis inactivates the COX-2/PGE2 pathway.

Citing Articles

Puerarin Alleviates Cerebral Ischemia-Reperfusion Injury by Inhibiting Ferroptosis Through SLC7A11/GPX4/ACSL4 Axis and Alleviate Pyroptosis Through Caspase-1/GSDMD Axis.

Huang Y, Yang J, Lu T, Shao C, Wan H Mol Neurobiol. 2025; .

PMID: 40056342 DOI: 10.1007/s12035-025-04798-5.


Aerobic Exercise Activates Fibroblast Growth Factor 21 and Alleviates Cardiac Ischemia/Reperfusion-induced Neuronal Oxidative Stress and Ferroptosis in Paraventricular Nucleus.

Zhao Y, Feng L, Wu C, Xu Y, Bo W, Di L Mol Neurobiol. 2025; .

PMID: 40009261 DOI: 10.1007/s12035-025-04780-1.


Identification of ferroptosis-related key genes in tuberculosis by bioinformatics methods.

Zhang W, Zhu D, Jiang H, Wang L AMB Express. 2025; 15(1):31.

PMID: 39984769 PMC: 11845653. DOI: 10.1186/s13568-025-01839-z.


p23 protects against ferroptosis of brain microvascular endothelial cells in ischemic stroke.

Zhao Y, Xu Y, Xu Q, He N, Zhao J, Liu Y Int J Mol Med. 2025; 55(4).

PMID: 39981897 PMC: 11878478. DOI: 10.3892/ijmm.2025.5505.


The emerging role and therapeutical implications of ferroptosis in wound healing.

Zhao Y, Chen Z, Xie S, Xiao F, Hu Q, Ju Z Burns Trauma. 2025; 13:tkae082.

PMID: 39958433 PMC: 11827611. DOI: 10.1093/burnst/tkae082.


References
1.
Sacco R, Kasner S, Broderick J, Caplan L, Connors J, Culebras A . An updated definition of stroke for the 21st century: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2013; 44(7):2064-89. PMC: 11078537. DOI: 10.1161/STR.0b013e318296aeca. View

2.
Benjamin E, Virani S, Callaway C, Chamberlain A, Chang A, Cheng S . Heart Disease and Stroke Statistics-2018 Update: A Report From the American Heart Association. Circulation. 2018; 137(12):e67-e492. DOI: 10.1161/CIR.0000000000000558. View

3.
Powers W, Rabinstein A, Ackerson T, Adeoye O, Bambakidis N, Becker K . Guidelines for the Early Management of Patients With Acute Ischemic Stroke: 2019 Update to the 2018 Guidelines for the Early Management of Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American.... Stroke. 2019; 50(12):e344-e418. DOI: 10.1161/STR.0000000000000211. View

4.
George P, Steinberg G . Novel Stroke Therapeutics: Unraveling Stroke Pathophysiology and Its Impact on Clinical Treatments. Neuron. 2015; 87(2):297-309. PMC: 4911814. DOI: 10.1016/j.neuron.2015.05.041. View

5.
Iadecola C, Anrather J . Stroke research at a crossroad: asking the brain for directions. Nat Neurosci. 2011; 14(11):1363-8. PMC: 3633153. DOI: 10.1038/nn.2953. View